Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Micro-RNA Expression Profiles in Localised Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03338712
Recruitment Status : Withdrawn (Principal Investigators no longer in business)
First Posted : November 9, 2017
Last Update Posted : November 9, 2017
Sponsor:
Information provided by (Responsible Party):
Wuerzburg University Hospital

Brief Summary:
Recurrence free survival The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association. Data will be updated once yearly for until death.

Condition or disease
Prostate Cancer Radical Prostatectomy

Layout table for study information
Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Micro-RNA Expression Profiles in Localised Prostate Cancer
Estimated Study Start Date : February 1, 2010
Estimated Primary Completion Date : April 1, 2016
Estimated Study Completion Date : April 1, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer




Primary Outcome Measures :
  1. Recurrence free survival [ Time Frame: Up to 120 months. From date of inclusion until date of death from any cause ]
    The patients will be followed in regular time intervals in accordance with the EAU-Guidelines (2010) and the S-3 Guideline for Prostate cancer of the German Urological Association.


Secondary Outcome Measures :
  1. Cancer specific survival [ Time Frame: Up to 120 months. From date of inclusion until date of death from any cause ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sampling Method:   Probability Sample
Criteria

Inclusion Criteria:

  • 35 Years to 80 Years
  • Male
  • Patients with clinically localised high risk prostate cancer

Exclusion Criteria:

-

Layout table for additonal information
Responsible Party: Wuerzburg University Hospital
ClinicalTrials.gov Identifier: NCT03338712    
Other Study ID Numbers: mi-RNA-PCa
First Posted: November 9, 2017    Key Record Dates
Last Update Posted: November 9, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases